StockData
Adagene Inc. logo

Adagene Inc. (ADAG) stock

ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 5/30
$1.48−0.12 (-7.50%)

Close on Nov 17, 2026Market cap $87.66MP/E –Yield –

Earnings

Adagene's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2023
$17.30M
Non-GAAP net loss per ordinary share, Q2 FY2023
$0.00
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Adagene's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q2 FY2026ended Jun 30, 2026Aug 12, 2026before the open––––Release
Q4 FY2025ended Dec 31, 2025Apr 1, 2026after the close––––Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close––––Release
Q4 FY2024ended Dec 31, 2024Mar 24, 2025before the open––––Release
Q2 FY2024ended Jun 30, 2024Jul 25, 2024after the close––––Release
Q4 FY2023ended Dec 31, 2023Jan 16, 2024after the close––––Release
Q2 FY2023ended Jun 30, 2023Aug 31, 2023before the open$17.30M–-$0.08$0.00Release
Q4 FY2022ended Dec 31, 2022Mar 28, 2023after the close––––Release
Q4 FY2021ended Dec 31, 2021Mar 31, 2022before the open––––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Adagene has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Adagene puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Adagene filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?